ProMIS Neurosciences
Manufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1920 Yonge St Ste 200, Toronto, Ontario,...Phone Number
(416) 847-6898Website
www.promisneurosciences.comRevenue
-Stock Symbol
PMNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada.Explore more
ProMIS Neurosciences Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ProMIS Neurosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once ProMIS Neurosciences has new funding data
Click to see if ProMIS Neurosciences had a recent Job posting/layoffs
Check if ProMIS Neurosciences has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at ProMIS Neurosciences
Earning: See what the market has to say on ProMIS Neurosciences recently announced quarterly report
ProMIS Neurosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ProMIS Neurosciences launches new products
Check out if ProMIS Neurosciences is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined ProMIS Neurosciences as Masked Content
Find more new buyers
Compare Similar Companies to ProMIS Neurosciences
Compare insights from companies similar to ProMIS Neurosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ProMIS Neurosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ProMIS Neurosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ProMIS Neurosciences.
ProMIS Neurosciences financials insights
Gather financial insights about ProMIS Neurosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$7M
2024
Share Placement
$3M
2025
Stock/Share Issuance
$800K
2026
Stock/Share Issuance
$175M
ProMIS Neurosciences Tech Stack
A closer look at the technologies used by ProMIS Neurosciences
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Artificial Intelligence
Person-Based
Medical Research
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Project
Research & Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
ProMIS Neurosciences News & Media
Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data
Promis Neurosciences (NASDAQ:PMN) reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers in patients with mild cognitive impairment due to Alzheimer’s disease and early Alzheimer’sProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
No ARIA-E observed across all genotypes, including APOE4 homozygotesProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will host a webinar on Tuesday, July 28, 2026, at 8:00 am ET, featuring Key Opinion Leaders (KOLs) Dr. Will Mantyh, Associate Professor with Tenure, University of Minnesota Medical School and Dr. Michael Weiner, Professor EmProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding ProMIS Neurosciences
Sign Up For FreeTo access detailed company insights
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada.... Read More
